Hikma, class plaintiffs to face off at US antitrust trial on May 19, judge says

( April 8, 2025, 18:37 GMT | Official Statement) -- MLex Summary: A California federal judge said today a May 2025 trial will "comprise the claims of Class Plaintiffs as against Hikma only." The class accuses Hikma of engaging in an anticompetitive scheme to delay entry of a generic version of narcolepsy drug Xyrem. In an order regarding trial structure, US District Judge Richard Seeborg said "[r]oping in Opt Out Plaintiffs' claims as against both Hikma and Jazz [Pharmaceuticals] will prejudice Class Plaintiffs' ability to make their case against only Hikma because significant time will be spent by Opt Out Plaintiffs presenting evidence regarding their claim about Jazz's alleged monopoly-evidence that Class Plaintiffs need not introduce." The trial is set to begin on May 19. Court document attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.

Know what others in the room don’t, with features including:

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Hikma, class plaintiffs to face off at US antitrust trial on May 19, judge says

Prepare for tomorrow’s regulatory change, today

Documents

Related Sections